Sorrento Therapeutics completes IgDraSol merger

Wednesday, September 11, 2013

Sorrento Therapeutics has completed its merger with Igdrasol, a privately-held company focused on the development of cancer therapeutics. Igdrasol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento’s common stock. Reflecting Sorrento’s recent reverse stock split, and based on the closing share price on Sept. 6, 2013, the transaction is valued at $28.2 million.

[Read More]